论文部分内容阅读
目的 :对长江流域6城市医院抗肿瘤药物用药的现状和趋势做出客观评估。方法 :调查、分析长江流域6城市138家医院1999年～2001年抗肿瘤药物用药金额、生产企业销售金额、临床应用情况。结果 :抗肿瘤药物用药金额1999年、2000年、2001年分别为19460、24421、32227万元 ,呈逐年上升趋势 ;医院平均每年每床位应用抗肿瘤药物金额为10238元。调查发现 ,一些新的抗肿瘤植物药和单抗药物正在进入市场 ,且基因疗法已在抗肿瘤治疗中初步展示其优势。结论 :抗肿瘤用药在医院占有重要地位,每床位占用金额较多 ,且逐年快速增长 ;抗肿瘤植物药、单抗药物和基因疗法将成为以后肿瘤治疗的主要趋势
Objective: To make an objective assessment of the status quo and trend of anti-tumor drugs in 6 city hospitals in the Yangtze valley. Methods: To investigate and analyze the amount of antitumor drugs used in 138 hospitals in 6 cities of the Yangtze River valley from 1999 to 2001, the sales amount and the clinical application of the manufacturing enterprises. Results: The amount of antineoplastic drugs used in 1999, 2000 and 2001 were 194,602,421,322.27 million yuan, showing an upward trend year by year; the average hospital for each bed application of anti-tumor drugs amounted to 10238 yuan. The survey found that some new antitumor botanical and monoclonal antibody drugs are entering the market and that gene therapy has shown its initial advantages in antitumor therapy. Conclusion: Antitumor drugs occupy an important position in the hospital, occupy more money per bed, and rapid growth year after year; anti-tumor plant drugs, monoclonal antibody drugs and gene therapy will become the main trend of future cancer treatment